Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

14.91 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 14.91
Bid (Size) 14.49 (1)
Ask (Size) 15.55 (1)
Prev. Close 14.91
Today's Range 14.91 - 14.91
52wk Range 11.81 - 21.85
Shares Outstanding 88,417,386
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients... 
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and... 
From Business Wire News Releases

Performance

YTD
-10.93%
-10.93%
1 Month
-4.97%
-4.97%
3 Month
-1.45%
-1.45%
6 Month
+13.30%
+13.30%
1 Year
-21.61%
-21.61%

More News

Read More
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
From Business Wire News Releases
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Business Wire News Releases
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
From Business Wire News Releases
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferat
From Business Wire News Releases
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tags GRTX Market News Pre/Market Outlook
From Benzinga
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
From Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.